Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.33 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656366 | 0.82 | ADRB2 (0.38) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL21632073 | 0.82 | CYP1A2 (0.47) | LMNA | |
| SCHEMBL21708797 | 0.78 | CASP1 (0.33) | CYP2D6CASP1ALDH1A1LMNAGLS | |
| SCHEMBL8770906 | 0.76 | ADRB2 (0.51) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL21656316 | 0.73 | NISCH (0.41) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL21656172 | 0.72 | PRSS1 (0.39) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL7441492 | 0.72 | MAPT (0.40) | LMNAHTT | |
| SCHEMBL26640409 | 0.71 | CYP2D6 (0.41) | CYP2D6CA2 | |
| SCHEMBL21708788 | 0.69 | ALDH1A1 (0.42) | ADRB2ADRB1CYP2D6NFKB1HIF1A | |
| SCHEMBL8770920 | 0.69 | MEN1 (0.42) | ADRB2ADRB1CYP2D6NFKB1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-110730776-A | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and their use | 拜耳股份公司 | 2020-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | ADRB2 871/4885ADRB1 1289/4885CYP2D6 1640/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | ADRB2 871/4885ADRB1 1289/4885CYP2D6 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.